Biotech IP valuation

01Overview and value chain#

Markers EC: Intellectual-property valuation & licensing-benchmark services | OECD: Bioeconomy policy & governance | Regulator: none — private valuation practice, not a licensed regulatory function

Biotech IP valuation is a B2B services category in which specialist consultancies and data platforms assign a defensible monetary value to a biotechnology or pharmaceutical company’s patent portfolio, supporting licensing negotiations, M&A due diligence, litigation damages and capital raises. Ocean Tomo runs engagement-based valuations for biotechnology startups, including a documented capital-raise engagement for a company holding IP covering cancer and rare-disease therapeutics and diagnostics. Consor IP Consulting applies AI-assisted methods to patent valuation, treating patents as strategic business assets rather than purely legal instruments. Charles River Associates (CRA) brings economic-valuation expertise to life-sciences disputes, including cases where the product being valued may never reach market — a distinctly biotech valuation problem. EverEdge Global, headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios. GreyB provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — built for IP counsel and licensing teams assessing monetization readiness, including standard-essential-patent (SEP) readiness reporting. Inngot, a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets for smaller biotech and life-sciences companies.

The key directions of biotech IP valuation are:

Engagement-based patent-portfolio valuation: custom valuations for a specific transaction — licensing negotiation, M&A, or a capital raise — grounded in the patent estate’s claims, remaining life and competitive position.
AI-assisted valuation methodology: applying machine-learning and data-driven models to patent valuation, moving beyond purely qualitative expert judgment.
Litigation and damages valuation: economic analysis supporting patent-infringement and licensing disputes, including cases involving products that have not yet reached market approval.
Portfolio analytics and monetization readiness: structured analysis of prosecution history, litigation exposure, claims and citations to assess which patents in a portfolio are genuinely ready for licensing or sale.

Sectoral value chain#

[Patent portfolio identification] ──> [Prior-art & claims analysis] ──> [Valuation methodology selection]
                                                                    │
                                                        (Royalty-rate benchmarking)
                                                                    │
              [Negotiation/litigation support] <──── [Valuation report delivery] <─── [Monetary value determination]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Portfolio identification	Cataloguing the patents, applications and other intangible assets that make up the biotech company’s IP estate.	In: Patent filings, R&D records. Out: IP asset inventory.
Prior-art and claims analysis	Assessing patent strength, remaining life, prosecution history and litigation exposure for each asset.	In: IP asset inventory, prosecution files. Out: Patent-strength assessment.
Valuation methodology selection	Choosing an income-, market- or cost-based valuation approach suited to the asset class and the transaction context.	In: Patent-strength assessment. Out: Selected valuation methodology.
Royalty-rate benchmarking	Comparing the asset against comparable licensing deals and royalty-rate data to ground the valuation in market evidence.	In: Selected valuation methodology, deal-comparable data. Out: Benchmarked royalty range.
Monetary value determination	Producing a defensible monetary valuation figure or range for the patent or portfolio.	In: Benchmarked royalty range. Out: Valuation figure/range.
Valuation report delivery	Delivering the finished valuation report to support the client’s licensing negotiation, M&A process or litigation.	In: Valuation figure/range. Out: Delivered valuation report.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Patent-valuation methodologies: income-, market- and cost-based approaches adapted to the specific characteristics of a biotech or pharmaceutical patent estate.
Royalty-rate benchmarking databases: structured datasets of comparable licensing deals used to ground a valuation in observed market royalty rates.
IP-portfolio analytics: software analyzing prosecution history, litigation exposure, claims and citations to assess a patent portfolio’s monetization readiness.

02US#

The United States hosts the largest concentration of biotech IP-valuation consultancies and royalty-rate data providers, several built on decades of patent-litigation and licensing-deal history.

Ocean Tomo’s engagement-based startup valuations, Consor’s AI-assisted methodology, CRA’s life-sciences litigation valuation#

Ocean Tomo: runs engagement-based IP valuations for biotechnology startups, including capital-raise support for companies holding therapeutic and diagnostic patent portfolios.
Consor IP Consulting: applies AI-assisted methods to patent valuation, treating patents as strategic business assets in a data-driven valuation practice.
Charles River Associates (CRA): brings economic-valuation expertise to life-sciences disputes, including the distinctly biotech problem of valuing a product that may never reach market approval.

03CN#

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese biotech IP-valuation firms searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Chinese biotech companies pursuing cross-border licensing or M&A typically engage the global valuation firms listed here, or domestic state-linked asset-appraisal institutions whose specific biotech-IP practices could not be confirmed in this screen.

Cross-border biotech IP valuation served by global consultancies#

Cross-border engagement pattern: Chinese biotech companies pursuing licensing deals or M&A with Western partners typically retain the global valuation firms listed in this article rather than a distinct domestic biotech-IP specialist.
Domestic gap: no Chinese-headquartered biotech IP-valuation firm confirmed by a live 2026 source was found during this screen.

04EU#

Europe and adjacent jurisdictions host specialist IP-valuation and intangible-asset consultancies serving smaller biotech and life-sciences clients alongside larger transactions.

EverEdge’s ten-asset-class valuation models, GreyB’s portfolio analytics, Inngot’s intangible-asset toolkit#

EverEdge Global: headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios.
GreyB: provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — including standard-essential-patent readiness reporting for licensing teams.
Inngot: a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets, sized for smaller biotech and life-sciences companies.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Ocean Tomo	🇺🇸 USA	Engagement-based IP valuation	Biotech startup capital-raise support	commercial
Consor IP Consulting	🇺🇸 USA	AI-assisted patent valuation	Data-driven valuation methodology	commercial
Charles River Associates IP	🇺🇸 USA	Economic/IP litigation valuation	Life-sciences disputes practice	commercial
EverEdge Global	🇳🇿 New Zealand	Ten-asset-class valuation models	Pharma/biotech IP asset coverage	commercial
GreyB	🇮🇳 India	IP Compass portfolio analytics	SEP readiness, litigation exposure analysis	commercial
Inngot	🇬🇧 United Kingdom	Intangible-asset valuation toolkit	Sized for smaller biotech clients	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The biotech IP-valuation technology stack combines established valuation methodology with AI-assisted analytics and structured royalty-benchmarking data:

Patent-valuation methodologies:
- Firms such as Ocean Tomo and Charles River Associates apply income-, market- and cost-based approaches adapted to biotech-specific circumstances, including products that have not yet reached regulatory approval.
AI-assisted valuation and portfolio analytics:
- Consor IP Consulting applies AI-assisted methods to patent valuation; GreyB’s IP Compass reviews prosecution history, litigation, claims and citations to assess monetization readiness.
Royalty-rate benchmarking:
- ktMINE maintains royalty-rate range data drawn from thousands of biopharma licensing deals, grounding valuations in observed market transactions.

07Value chains and production pipelines#

Industrial pipeline for a biotech patent-portfolio valuation engagement#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Patent portfolio         │ ───> │ 2. Prior-art & claims       │
│    identification                │      │    analysis                      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Royalty-rate             │ <─── │ 3. Valuation methodology    │
│    benchmarking                 │      │    selection                     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Monetary value           │ ───> │ 6. Valuation report         │
│    determination                │      │    delivery                      │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for a biotech patent-portfolio valuation engagement

Stage 1: Patent portfolio identification

The valuation firm catalogues the patents, applications and other intangible assets that make up the biotech company’s IP estate.

Stage 2: Prior-art and claims analysis

Analysts assess patent strength, remaining life, prosecution history and litigation exposure for each asset in the portfolio.

Stage 3: Valuation methodology selection

An income-, market- or cost-based valuation approach is selected to fit the specific asset class and the transaction context (licensing, M&A, litigation, capital raise).

Stage 4: Royalty-rate benchmarking

The asset is compared against comparable licensing deals and royalty-rate data to ground the valuation in observed market evidence rather than pure theory.

Stage 5: Monetary value determination

The methodology and benchmark data are combined to produce a defensible monetary valuation figure or range for the patent or portfolio.

Stage 6: Valuation report delivery

The finished valuation report is delivered to support the client’s licensing negotiation, M&A process, capital raise or litigation.

Supplier	Region & tags
Ocean Tomo	US
Consor IP Consulting	US
Charles River Associates	US
EverEdge Global	EU
GreyB	India
Inngot	EU

AI Recommendation

Key directions:

Engagement-based patent-portfolio valuation — custom valuations for a specific transaction (licensing, M&A, capital raise) grounded in the patent estate’s claims, remaining life and competitive position.
AI-assisted valuation methodology — machine-learning and data-driven models applied to patent valuation, beyond purely qualitative expert judgment.
Litigation and damages valuation — economic analysis supporting patent-infringement and licensing disputes, including products that have not yet reached market approval.
Portfolio analytics and monetization readiness — structured analysis of prosecution history, litigation exposure, claims and citations to assess which patents are genuinely ready to license or sell.

Regulatory:

There is no regulator or licensing body governing IP valuation itself — this is a private consulting practice, not a regulated profession, though the underlying patents are subject to normal patent-office prosecution and litigation.
Valuing a biotech patent before its underlying product has regulatory approval is a distinct challenge from valuing an already-commercialized asset, since the value depends on an approval probability rather than realized revenue.
A valuation used in litigation or a licensing dispute must withstand adversarial scrutiny, which is why firms like Charles River Associates emphasize defensible, evidence-grounded methodology over a single expert opinion.

Companies not in table: ktMINE, a US royalty-rate benchmarking data provider, was confirmed by a live source but held back to keep the table at six rows — it is referenced in the tech-stack section instead; Aon IP Solutions and two Chinese candidates returned no confirming live source and were excluded rather than tabled from general knowledge.

Category boundary: this is distinct from patent-prosecution or freedom-to-operate legal services — the deliverable here is a monetary figure for negotiation, litigation or accounting purposes, not a filing strategy or infringement opinion.

Processing note: no health authority or standards body regulates this category, since IP valuation is a private advisory practice rather than a licensed function.